Skip to content
★ Sign in to follow
MM

M M Slaoui

GlaxoSmithKline plc
Total declarations
10
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (0 ops.)
—

Latest filing published 23 Feb 2017 for GlaxoSmithKline plc, €2,063.

Insider track record

Disclosed buys
0
Disclosed sells
0
Signal history

No signal scores available.

M M Slaoui: trading record in brief

This profile gathers the share dealings of M M Slaoui in GlaxoSmithKline plc. We count 10 filings; the first trade dates from 13 October 2016 and the latest from 22 February 2017.

The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.

The record was last updated on 23 February 2017 with a share grant (€2,063) in GlaxoSmithKline plc. The median gap between a trade and its publication by RNS (LSE) is 1 day. Under the UK Market Abuse Regulation, managers have three business days to notify their trades. Source: insider filings from RNS (LSE). Past trades are no guide to future returns.

Companies and markets linked to M M Slaoui

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations10 total
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    2,175 USD0FCA-NSM
    53 shares@ US$41.03n/aISIN US37733W1053FCA-NSM:LSE20170223150705_13137787_20200330131514111_16478-0
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    506,557 USD0FCA-NSM
    12,486 shares@ US$40.57n/aISIN US37733W1053FCA-NSM:LSE20170220141240_13133237_20200330131513994_13406-0
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    0FCA-NSM
    44,292 shares0n/aISIN US37733W1053FCA-NSM:LSE20170217155818_13131902_20200330131513963_12745-11
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    0FCA-NSM
    28,860 shares0n/aISIN US37733W1053FCA-NSM:LSE20170217155702_13131901_20200330131513963_12744-6
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    431,584 USD0FCA-NSM
    10,760 shares@ US$40.11n/aISIN US37733W1053FCA-NSM:LSE20170217155510_13131899_20200330131513963_12743-9
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    1,144 USD0FCA-NSM
    29 shares@ US$39.46n/aISIN US37733W1053FCA-NSM:LSE20170208172733_13121737_20200330131513704_5427-0
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    852 USD0FCA-NSM
    22 shares@ US$38.74n/aISIN US37733W1053FCA-NSM:LSE20161104171250_013025456_20200330143612080_4507-0
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    454 USD0FCA-NSM
    10.943 shares@ US$41.4813NYSE (XNYS)ISIN US37733W1053FCA-NSM:LSE20161021161201_013009798_20200330143616568_16565-0
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    11,305 USD0FCA-NSM
    244.955 shares@ US$46.1526New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:LSE20161018070005_013003822_20200330143616379_12367-0
  • ◆
    Chairman, Global VaccinesExecutivesGlaxoSmithKline plc
    202,710 USD0FCA-NSM
    4,782.022 shares@ US$42.39n/aISIN US37733W1053FCA-NSM:LSE20161018070005_013003824_20200330143616379_12373-0

10 of 10 declarations